Equities
Health CareMedical Equipment and Services
  • Price (USD)581.21
  • Today's Change1.84 / 0.32%
  • Shares traded1.03m
  • 1 Year change+4.87%
  • Beta0.7972
Data delayed at least 15 minutes, as of Mar 28 2024 20:10 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Thermo Fisher Scientific Inc. is engaged in helping life sciences research, increasing laboratory productivity, and improving patient health through diagnostics and the development and manufacture of life-changing therapies. The Company's Life Sciences Solutions segment provides a portfolio of reagents, instruments and consumables used in biological and medical research, discovery and production of new drugs and vaccines as well as diagnosis of infection and disease. Analytical Instruments segment provides instruments and the supporting consumables, software and services that are used for a range of applications in the laboratory and in the field. Specialty Diagnostics segment offers a range of diagnostic test kits, reagents, culture media, instruments and associated products to serve customers in healthcare, clinical, pharmaceutical, industrial, and food safety laboratories. The Laboratory Products and Biopharma Services segment offers virtually everything needed for the laboratory.

  • Revenue in USD (TTM)42.86bn
  • Net income in USD6.00bn
  • Incorporated1960
  • Employees122.00k
  • Location
    Thermo Fisher Scientific Inc168 Third AvenueWALTHAM 02451United StatesUSA
  • Phone+1 (781) 622-1000
  • Fax+1 (781) 622-1207
  • Websitehttps://www.thermofisher.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
TMO:NYQ since
announced
Transaction
value
CorEvitas LLCDeal completed06 Jul 202306 Jul 2023Deal completed11.64%912.50m
MarqMetrix IncDeal completed21 Jun 202321 Jun 2023Deal completed10.20%--
Data delayed at least 15 minutes, as of Mar 28 2024 20:10 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
DexCom Inc3.62bn541.50m53.77bn9.60k108.8025.9973.9114.841.281.288.555.370.62153.044.29377,322.909.298.3013.1110.5063.6565.9014.9514.142.48--0.54650.0024.4928.5658.70--28.66--
Edwards Lifesciences Corp6.00bn1.40bn57.21bn19.80k41.348.6037.059.532.302.309.8511.060.68021.358.47303,272.7015.8516.6318.2119.1277.0276.7123.3024.842.40--0.08160.0011.5610.03-7.8513.701.96--
Becton Dickinson and Co19.49bn1.27bn71.22bn73.00k56.262.8120.083.654.384.2367.2587.680.36993.318.57267,013.702.472.372.892.7041.3745.786.686.950.64356.450.388781.232.663.92-4.8512.97-0.47373.94
Boston Scientific Corporation14.24bn1.57bn100.86bn48.00k64.075.2236.477.081.071.079.7313.160.42131.996.78296,666.704.712.505.432.9169.6568.8411.186.470.81705.160.31790.0012.297.71144.55-0.42767.82--
Medtronic PLC32.32bn4.20bn115.41bn95.00k27.562.2316.713.573.153.1524.2738.950.34952.005.45340,210.504.584.785.285.3765.7367.6813.1014.281.7130.780.326372.49-1.450.8366-25.42-6.956.448.13
Stryker Corp20.50bn3.17bn136.40bn52.00k43.497.3332.536.658.258.2553.4248.920.53381.675.59394,192.308.246.6010.127.8463.9063.9915.4413.130.9689--0.411443.7011.118.5534.229.680.104710.16
Intuitive Surgical, Inc.7.12bn1.80bn141.81bn13.68k79.5710.5962.4219.915.035.0319.9337.770.50142.276.88520,919.9012.7912.4214.4413.8366.3967.6025.5126.314.02--0.000.0014.4913.8535.989.7741.53--
Abbott Laboratories40.11bn5.72bn196.91bn114.00k34.685.1021.964.913.273.2722.9322.260.54332.816.28351,833.307.757.729.719.3955.3256.7314.2714.391.1622.940.274354.95-8.125.58-17.4518.369.5712.74
Thermo Fisher Scientific Inc42.86bn6.00bn220.92bn122.00k37.504.7923.455.1515.4515.45110.46120.870.43764.804.49351,286.906.147.797.319.1139.9044.9414.0316.761.3916.340.42716.75-4.5811.96-13.7414.4314.3015.39
Data as of Mar 28 2024. Currency figures normalised to Thermo Fisher Scientific Inc's reporting currency: US Dollar USD

Institutional shareholders

30.94%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 31 Dec 202331.33m8.22%
BlackRock Fund Advisorsas of 31 Dec 202317.17m4.50%
SSgA Funds Management, Inc.as of 31 Dec 202316.48m4.32%
Capital Research & Management Co. (World Investors)as of 31 Dec 202312.26m3.22%
T. Rowe Price Associates, Inc. (Investment Management)as of 31 Dec 20239.35m2.45%
Capital Research & Management Co. (Global Investors)as of 31 Dec 20237.99m2.10%
Geode Capital Management LLCas of 31 Dec 20237.29m1.91%
Fidelity Management & Research Co. LLCas of 31 Dec 20236.46m1.70%
Norges Bank Investment Managementas of 31 Dec 20235.48m1.44%
Massachusetts Financial Services Co.as of 31 Dec 20234.18m1.10%
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.